TABLE 2.
Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors compared to DPP‐4 inhibitors, Sulfonylurea, and Thiazolidinedione
| Outcome | SGLT‐2 inhibitors | Compare group | HR (95% CI) | ||
|---|---|---|---|---|---|
| No. of events | Incidence rate (Per 1000 PY) | No. of events | Incidence rate (Per 1000 PY) | ||
| SGLT‐2 inhibitors (n = 7738) versus DPP‐4 inhibitors (n = 7738) | |||||
| Genital infections | 473 | 67.2 | 356 | 32.2 | 2.39 (2.07–2.76) |
| Urinary tract infections | 543 | 77.0 | 613 | 55.4 | 1.57 (1.39–1.77) |
| SGLT‐2 inhibitors (n = 7145) versus Sulfonylurea (n = 7145) | |||||
| Genital infections | 413 | 63.1 | 275 | 15.0 | 3.23 (2.73–3.81) |
| Urinary tract infections | 492 | 75.1 | 608 | 45.5 | 1.66 (1.47–1.89) |
| SGLT‐2 inhibitors (n = 2175) versus Thiazolidinedione (n = 2175) | |||||
| Genital infections | 114 | 56.7 | 74 | 21.2 | 3.23 (2.35–4.44) |
| Urinary tract infections | 146 | 72.7 | 180 | 51.6 | 1.69 (1.33–2.13) |